Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jun 23;26(13):3830.
doi: 10.3390/molecules26133830.

Alnus sibirica Compounds Exhibiting Anti-Proliferative, Apoptosis-Inducing, and GSTP1 Demethylating Effects on Prostate Cancer Cells

Affiliations

Alnus sibirica Compounds Exhibiting Anti-Proliferative, Apoptosis-Inducing, and GSTP1 Demethylating Effects on Prostate Cancer Cells

Seo-Yeon Seonu et al. Molecules. .

Abstract

Alnus sibirica (AS) is distributed in Korea, Japan, China, and Russia and has reported anti-oxidant, anti-inflammatory, and reducing activities on atopic dermatitis-like skin lesions, along with other beneficial health properties. In the present study, we tried to prove the cancer-preventive activity against prostate cancer. The extracted and isolated compounds, oregonin (1), hirsutenone (2), and hirsutanonol (3), which were isolated from AS, were tested for anti-proliferative activity. To do this, we used the MTT assay; NF-κB inhibitory activity, using Western blotting; apoptosis-inducing activity using flow cytometry; DNA methylation activity, using methylation-specific polymerase chain reaction in androgen-dependent (LNCaP) and androgen-independent (PC-3) prostate cancer cell lines. The compounds (1-3) showed potent anti-proliferative activity against both prostate cancer cell lines. Hirsutenone (2) exhibited the strongest NF-κB inhibitory and apoptosis-inducing activities compared with oregonin (1) and hirsutanonol (3). DNA methylation activity, which was assessed for hirsutenone (2), revealed a concentration-dependent enhancement of the unmethylated DNA content and a reduction in the methylated DNA content in both PC-3 and LNCaP cells. Overall, these findings suggest that hirsutenone (2), when isolated from AS, may be a potential agent for preventing the development or progression of prostate cancer.

Keywords: Alnus sibirica; DNA methylation; cancer prevention; hirsutenone; prostate cancer.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Structures of the three diarylheptanoids isolated from Alnus sibirica, oregonin (1); hirsutenone (2); hirsutanonol (3).
Figure 2
Figure 2
NF-kB inhibitory activities of oregonin (1), hirsutenone (2), and hirsutanonol (3) in PCa cell lines. A: PC-3 cell; B: LNCaP cell. The results were expressed as mean ± SD of triplicate experiments (n = 3). NC: Normal control group. *: p < 0.05, **: p < 0.01, ***: p < 0.001, compared with the normal control group.
Figure 3
Figure 3
Apoptosis-inducing activities of various concentrations of oregonin (1), hirsutenone (2), and hirsutanonol (3) in PCa cell line. (A): PC-3 cells; (B): LNCaP cell. The results are expressed as mean ± SD of triplicate experiments (n = 3). BAY: positive control. Letters a–o in the same column indicate significant differences, p < 0.05.
Figure 3
Figure 3
Apoptosis-inducing activities of various concentrations of oregonin (1), hirsutenone (2), and hirsutanonol (3) in PCa cell line. (A): PC-3 cells; (B): LNCaP cell. The results are expressed as mean ± SD of triplicate experiments (n = 3). BAY: positive control. Letters a–o in the same column indicate significant differences, p < 0.05.
Figure 4
Figure 4
DNA methylation activity of hirsutenone (2) in PCa cell lines. (A,C): relative unmethylated DNA contents in PC-3 and LNCaP cell lines; (B,D): relative methylated DNA contents in PC-3 and LNCaP cell lines. The results were expressed as the mean ± SD of triplicate experiments (n = 3). NC: Normal control group. *: p < 0.05, **: p < 0.01, compared with the normal control group.

Similar articles

Cited by

References

    1. Grönberg H. Prostate cancer epidemiology. Lancet. 2003;361:859–864. doi: 10.1016/S0140-6736(03)12713-4. - DOI - PubMed
    1. Rawla P. Epidemiology of prostate cancer. World J. Oncol. 2019;10:63. doi: 10.14740/wjon1191. - DOI - PMC - PubMed
    1. Bostwick D.G., Burke H.B., Djakiew D., Euling S., Ho S.M., Landolph J., Morrison H., Sonawane B., Shifflett T., Waters D.J. Human prostate cancer risk factors. Cancer Interdiscip. Int. J. Am. Cancer Soc. 2004;101:2371–2490. doi: 10.1002/cncr.20408. - DOI - PubMed
    1. Ding Y.C., Wu H., Davicioni E., Karnes R.J., Klein E.A., Den R.B., Steele L., Neuhausen S.L. Prostate cancer in young men represents a distinct clinical phenotype: Gene expression signature to predict early metastases. J. Transl. Genet. Genom. 2021;5:50. - PMC - PubMed
    1. Barnes S. Role of phytochemicals in prevention and treatment of prostate cancer. Epidemiol. Rev. 2001;23:102–105. doi: 10.1093/oxfordjournals.epirev.a000773. - DOI - PubMed

MeSH terms